Is Danggui Safe to be Taken by Breast Cancer Patients?—A Skepticism Finally Answered by Comprehensive Preclinical Evidence-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Is Danggui Safe to be Taken by Breast Cancer Patients?—A Skepticism Finally Answered by Comprehensive Preclinical Evidence

Published:2019-06-25 Issue: Volume:10 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Yue Grace Gar-Lee,Wong Lok-Sze,Leung Hoi-Wing,Gao Si,Tsang Julia Yuen-Shan,Lin Zhi-Xiu,Law Bonita Ka-Bo,Tse Gary Man-Kit,Lau Clara Bik-San

Funder

Health and Medical Research Fund

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference49 articles.

1. Estrogenic activity of herbs commonly used as remedies for menopausal symptoms;Amato;Menopause,2002

2. Trends in complementary/alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005;Boon;BMC Womens Health,2007

3. Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells;Chang;Eur. J. Clin. Invest.,2006

4. The impact of chemotherapy in cancer patients: reflection on traditional Chinese symptom complex, cancer-related fatigue, and quality of life;Chien;Holist. Nurs. Pract.,2013

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A comprehensive review of antitumor properties of Angelica species and their antitumor‐responsible constituents and the underlying molecular mechanisms involved in tumor inhibition;Phytotherapy Research;2023-04-22

2. Natural product Eriocalyxin B suppressed triple negative breast cancer metastasis both in vitro and in vivo;Biochemical Pharmacology;2023-04

3. Traditional Chinese Medicine: A Class of Potentially Reliable Epigenetic Drugs;Frontiers in Pharmacology;2022-06-14

4. Tumorigenic risk of Angelica sinensis on ER-positive breast cancer growth through ER-induced stemness in vitro and in vivo;Journal of Ethnopharmacology;2021-11

5. Influence of cultural practices on breast cancer risks, stage at presentation and outcome in a multi‑ethnic developing country (Review);Oncology Letters;2021-09-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3